Lingtao Jin, PhD

ljin1Assistant Professor

Office: CGRC 456
Phone: (352)

Education and Training

PhDPharmacology, Institute of Biophysics, Chinese Academy of Sciences, China 2010
BSBio-engineering, Shenyang Pharmaceutical University, China 2004

Postdoctoral Training

Postdoctoral FellowCancer metabolism, Dept. Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia

Research Interests

My research interest is focused on understanding the signaling basis of cancer metabolism, with focus on the function of metabolic enzymes and onco-metabolites in cancer and drug resistance. An ultimate goal is to apply the obtained insights to the development of molecular-targeted therapies to treat human cancers.

Ongoing Research Support

  • American Cancer Society Institutional Research Grant: IRG 17-181-04
    Cancer Society (ACS) Jin L (PI) 01/01/18-12/31/18
    The functional role of AGGF1 in taxol resistant cancer
    The goal of this project is to characterize the role of AGGF1 and its downstream effectors in driving taxol resistance and validate AGGF1 as a novel predictive marker and a therapeutic target to overcome taxol resistance in cancer.
    Role: Principle Investigator

Professional Societies

American Association for Cancer Research (AACR): 2012 – Present


Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf independent MEK activation. (2018). Cancer Cell, 34(2):315-330.-Featured in: Cancer Cell. 34(2):183-185 | PubMed

Zeng W, Jin L*, Zhang F, Zhang C, and Liang W*. Naringenin as a Potential Immunomodulator in Therapeutic. (2018). Pharmacological Research, 135:122-126. | | (*Corresponding author)

Jin L*, Chun J, Pan C, Kumar A, Zhang G, Ha Y, Li Dan, Alesi GN, Kang Y, Zhou L, Yu W-W, Magliocca KR, Khuri FR, Qu C-K, Metallo C, Owonikoko TK and Kang S*. The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. (2017). Molecular Cell 69(1):87-99 | PubMed | (*Corresponding author) – Featured in: Molecular Cell 69(1):1-2

Jin L, Zeng W, Zhang F, Zhang C, Liang W. Naringenin ameliorates acute inflammation by regulating intracellular cytokine degradation. (2017). Journal of Immunology 199(10):3466-3477. | PubMed

Jin L*, Chun J*, Pan C, Alesi GN, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Fan J, Kang S. Y10 phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumor metastasis. (2017). Oncogene 36(27):3797-3806. | PubMed | (*Co-first author)

Jin L*, Alesi GN, Kang S*. Glutaminolysis as a target for cancer therapy. (2016). Oncogene 35(28):3619-25. | PubMed | (*Corresponding author)

Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. (2015). Cancer Cell 27(2):257-70. | PubMed

Jin L, Li D, Lee JS, Elf S, Alesi GN, Fan J, Kang HB, Wang D, Fu H, Taunton J, Boggon TJ, Tucker M, Gu TL, Chen ZG, Shin DM, Khuri FR, Kang S. p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and-Independent Mechanisms. (2013). Molecular and Cellular Biology 33(13), 2574-2585. | PubMed

Du G*, Jin L*, Han X, Song Z, Zhang H, Liang W. Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. (2009). Cancer Research 69(7), 3205-3212. | PubMed | (*Co-first authors)

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J. (2017). Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism 25(2):358-373. | PubMed

Visit Pubmed for a full list of references